The outcomes of growth hormone therapy in the obstructive sleep apnea parameters of Prader-Willi syndrome patients: a systematic review.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of sleep apnea (obstructive), published as a systematic review.

Prader-Willi syndrome is a serious genetic condition, capable of causing endocrinological imbalance, which has as one of its main treatments the growth hormone therapy.

However, this therapy still causes some uncertainty concerning its effects on the respiratory parameters of those patients, especially in cases of obstructive sleep apnea, therefore, presenting a need for the analysis of the relationship between the therapy and the otolaryngologic condition.

How the Review Was Done

A systematic review following the PRISMA model was developed, with searches for keywords made in the databases PubMed (MEDLINE), Scopus, and Web of Science and registration in the PROSPERO platform (CRD42023404250).

What Was Measured

Topics PubMed links to this paper include Prader-Willi Syndrome, Growth Hormone, Sleep Apnea, Obstructive, Human Growth Hormone and Pharynx.

Author keywords: Obstructive sleep apnea and Prader–Willi syndrome.

What This Means in Plain Language

This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in people with sleep apnea (obstructive).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Sleep apnea (obstructive) research.